{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epstein-Barr+Virus+Specific+T-Lymphocytes", "query": { "intervention": "Epstein-Barr Virus Specific T-Lymphocytes" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epstein-Barr+Virus+Specific+T-Lymphocytes&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T10:57:02.195Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006100", "title": "Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": null, "start_date": "2000-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006100" }, { "nct_id": "NCT02532452", "title": "Third Party Viral Specific T-cells (VSTs)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Viral Infection", "Viral Reactivation", "Infection in an Immunocompromised Host" ], "interventions": [ { "name": "Viral Specific VST Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Days", "maximum_age": null, "sex": "ALL", "summary": "2 Days and older" }, "enrollment_count": 1000, "start_date": "2015-09-02", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 4, "location_summary": "Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio", "locations": [ { "city": "Akron", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02532452" }, { "nct_id": "NCT00834093", "title": "A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Epstein-Barr Virus Specific Immunotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2009-04", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00834093" }, { "nct_id": "NCT00058617", "title": "Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epstein-Barr Virus-Related Hodgkin Lymphoma", "Epstein-Barr Virus-Related Non-Hodgkin Lymphoma", "EBV Positive Plasma Cell Neoplasm" ], "interventions": [ { "name": "Injection of EBV Specific CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 13, "start_date": "1996-01", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058617" }, { "nct_id": "NCT06176690", "title": "Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD30-Positive Diffuse Large B-Cell Lymphoma", "Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Peripheral T-cell Lymphoma", "Anaplastic Large Cell Lymphoma, ALK-negative", "Non-Hodgkin Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "C7R.CD30.CAR-EBVST cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2025-10-27", "completion_date": "2043-06-27", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06176690" }, { "nct_id": "NCT00431210", "title": "Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Epstein-Barr virus-specific adoptive T-cells immunotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2007-02", "completion_date": "2016-01-26", "has_results": false, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00431210" }, { "nct_id": "NCT00383097", "title": "Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkins Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES", "type": "GENETIC" }, { "name": "LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 6, "start_date": "2006-09", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2012-05-24", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00383097" }, { "nct_id": "NCT02763254", "title": "Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Lymphoma, Large B-Cell, Diffuse", "Post-transplant Lymphoproliferative Disorder" ], "interventions": [ { "name": "baltaleucel-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cell Medica Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1, "start_date": "2016-11", "completion_date": "2018-02-17", "has_results": true, "last_update_posted_date": "2019-03-26", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02763254" }, { "nct_id": "NCT02108522", "title": "Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infection" ], "interventions": [ { "name": "Multivirus Specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AlloVir", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 82, "start_date": "2014-06", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2021-07-20", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02108522" }, { "nct_id": "NCT04013802", "title": "TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Viral Infection" ], "interventions": [ { "name": "HLA-matched VSTs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "2021-03-08", "completion_date": "2031-05-01", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-30T10:57:02.195Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04013802" } ] }